title: Effect of selenium supplementation on mice infected with LP-BM5 MuLV, a murine AIDS model.
abstract: LP-BM5 Murine leukemia virus (MuLV) infection of C57BL/6 mice develop a disease that has many features in common with human acquired immunodeficiency syndrome (AIDS), in particular abnormal lymphoproliferation and severe immunodeficiency. Thus, this MAIDS model may be useful for evaluation of potent antirival agents in vivo. Deficiency in antioxidant micronutrients such as selenium, zinc, and glutathione have been observed in AIDs and AIDS-related complex (ARC) patients. In the present study, the MAIDS model was used to evaluate immunological and oxidative effect of Se as sodium selenite. Results indicated that Se treatment 0.1 mg/kg/d (p.o.) inhibited splenomegaly and sera IgG elevation effectively. In addition to abnormal immunity, oxidative imbalance possibly existed in MAIDS model, as lipid peroxide increased significantly in spleen and whole blood glutathione peroxidase (GSH-Px) activity decreased markedly. Se supplementation had good protective effect.
authors.affiliation: Department of Chemistry, Huazhong University of Science and Technology, Wuhan, PROC.
authors.forename: C
authors.initials: C
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Zhou
authors.forename: H
authors.initials: H
authors.lastname: Xu
authors.forename: Y
authors.initials: Y
authors.lastname: Jiang
authors.forename: G
authors.initials: G
authors.lastname: Zhu
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000378:metabolism / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D015227:Lipid Peroxidation; D051379:Mice; D008810:Mice, Inbred C57BL; D016183:Murine Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D012643:Selenium / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D013154:Spleen / Q000378:metabolism; D013163:Splenomegaly / Q000188:drug therapy; D013482:Superoxide Dismutase / Q000378:metabolism; D015215:Zidovudine / Q000378:metabolism / Q000627:therapeutic use*; D015032:Zinc / Q000378:metabolism
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine; D013482:Superoxide Dismutase; D012643:Selenium; D015032:Zinc